Sales and innovation rising fast for sedatives & sleep aids

CHCINACTION

Covid-19’s impact on the consumer healthcare market is now well-established, with a notable spike in sales of certain CHC subcategories like analgesics, vitamin C supplements and antiseptics & disinfectants. Indeed, a fascinating recent report in the FT story reveals the lengths that RB has gone to in order to maintain supply of antiseptic brand Dettol during the pandemic. In addition, we’re also seeing some perhaps less expected upsurges in demand for other products as a result of Covid-19, for example eye care treatments and sedatives & sleep aids.

In the latter case, anxiety caused by the pandemic is leading consumers to seek refuge in products that promote relaxation and reduce stress. In response to this trend, US retailer CVS has this month created a new “Calm & Comfort” section in thousands of its pharmacies to accommodate this growing need for stress relief products, from weighted blankets and aromatherapy to supplements that promote enhanced mood and sleep, according to a report in WWD. Even before Covid-19, we were noticing a clear upturn in sales of sedatives & sleep aids, partly driven by rising NPD activity – as demonstrated by the chart below – and the pandemic is accelerating this trend.

Sedatives + sleep, 2017-19

According to CHC New Products Tracker, NPD activity in the sedatives & sleep aids subcategory reached an all-time high in 2019 (with almost 150 entries added to the database), and this upsurge in innovation was reflected in global sales growth, which accelerated to 7.3% in 2019 according to DB6, driven by the US market. Notable developments so far in this subcategory in 2020 include P&G’s New Chapter One Daily Multiherbal Stress Relief and Sleep Well products, as well as R3set, which will be a key feature of CVS’ new Calm & Comfort section. 

R3set, a new brand focused on helping people to manage stress, was recently launched in selected Target and 4,400+ CVS stores. The first two dietary supplements – citrus mint-flavoured Calm (l-theanine, valerian root + ahiflower) and lavender mint-flavoured Unwind (ashwagandha, passion flower + chamomile) – are formulated by co-Founder Dr Eric First, along with development partner Lonza. Each microdose capsule is coated with aromatherapy oils to provide a soothing experience and the products come with instructions for a simple breathing exercise. The supplements retail for US$19.99 for a 14-count bottle; 14-day combo packs cost US$34.99 and 5-day starter packs US$14.99. 

Where will NPD take the CHC market in the future? Find out in our recently published report, Innovation in CHC: NPD & Innovation in CHC under the Spotlight! This report, drawing on Nicholas Hall’s CHC New Products Tracker, assesses the global picture of CHC innovation, featuring ingredient trends, delivery format trends, analysing innovation trends by region and by marketer, plus much more! To order your copy, or for more information, please contact melissa.lee@NicholasHall.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s